Life Science Specialists in China and Japan are Distributing the Ultra-Sensitive Multiplexed ICE COLD-PCR™-Based ICEme Kits that Work with Liquid Samples and on all Sequencing Platforms
OMAHA, Neb. (AUGUST 27, 2015) — Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced the addition of distributors in China and Japan for its ICEme™ Mutation Enrichment Kits for genomics research. The recently-launched kits use Transgenomic’s Multiplexed ICE COLD-PCR™ (MX-ICP) technology and are designed to facilitate genomics-based cancer research. The new distributors include Spectron Scientific Co., Ltd. in China and Sowa Trading Co., Inc., in Japan, who are established suppliers of advanced life science products to researchers at universities, pharmaceutical and biotech companies, and research institutes in their respective markets.
“Asia represents important and growing markets for cancer research, and our ICEme Kits will allow researchers in China and Japan to use the sequencing platforms already in their labs to conduct sophisticated genetic analyses to accelerate their cancer research and drug discovery programs,” commented Paul Kinnon, President and Chief Executive Officer of Transgenomic. “We expect to announce additional distributors in other key territories soon.”
MX-ICP technology delivers ultra-high sensitivity, providing up to a 500-fold increase in mutation detection compared to most current methods, with levels of detection routinely achievable down to 0.01%. ICEme Kits work well with most patient samples, including tissue, blood, plasma, urine and other biofluids. The kits are simple to use and they work with most of the analytic platforms commonly available in research laboratories today. They are easily customizable for use with single mutations or in combination. The initial menu includes 17 clinically relevant, actionable mutations that are associated with important cancers such as colorectal, lung and breast cancer, and melanoma. Additional mutations are being added on an ongoing basis.
Multiplexed ICE COLD-PCR was discovered in the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic.
Additional information on the ICEme kits is available at www.transgenomic.com/products/iceme-kits-overview/.
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™ and its unique genetic tests provided through its Patient Testing business. Transgenomic also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to the expected timing for the availability of additional mutations with the ICEme kits, the potential uses for the ICEme kits, the effectiveness of the ICEme kits and Multiplexed ICE COLD-PCR technology, the availability of the ICEme kits for diagnostic use and expectations regarding the ICEme kits’ and Multiplexed ICE COLD-PCR’s ability to facilitate the development of Transgenomic’s pipeline. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s filings with the Securities and Exchange Commission, including in Transgenomic’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 15, 2015. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
BLL Partners LLC
Barbara Lindheim, 212-584-2276